A minimum of 3 years of sustained clinical remission may protect against an increase in disease activity and the development ...

The FDA has agreed to review an application from Roche that seeks approval in the U.S. of obinutuzumab as a treatment for ...

The other side of the coin is that a lot of our patients come in, and they already have damage to the kidney because the diagnosis of lupus nephritis is often made after proteinuria has achieved a ...

Autoimmune diseases make the immune system attack healthy tissues. These can affect organs like kidneys, leading to ...

Research shows multiple factors drive CKD risk in lupus nephritis, including nephritic flares, baseline hypertension, renal ...

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva®) for the treatment of lupus nephritis.  Obinutuzumab is a monoclonal ...

Systemic lupus erythematosus, or lupus, is a complex autoimmune disease in which the immune system mistakenly attacks healthy ...

Lupus nephritis affects 1.7 million people worldwide; up to one-third of people on current treatments will progress to end-stage kidney disease within 10 years2-5 ...

People with diabetes and high blood pressure are more susceptible to chronic kidney disease. Know treatment options, ...

The National Kidney Foundation (NKF) is proud to announce that its KidneyCARE (Community Access to Research Equity)™ Study – ...